[27] discussed differences in effective concentrations between experimental conditions (i.e., the concentrationresponse curve to agonists shifted to the right by two or more orders of magnitude and the GLP-1 effects in the nanomolar range were within the acceptable physiological range)
The activation of the RAAS, particularly through angiotensin II, can influence myocardial energy metabolism

Patients should contact their healthcare provider if they experience: Persistent vomiting lasting more than 24 hours or inability to keep down fluids, which raises concern for dehydration Signs of dehydration including decreased urination, dark urine, dizziness upon standing, extreme thirst, or dry mouth Severe abdominal pain , particularly if constant and radiating to the back, which may indicate pancreatitisa rare but serious adverse effect Hypoglycemia symptoms including sweating, tremor, palpitations, confusion, dizziness, or irritabilityespecially in patients taking concurrent insulin or sulfonylureas Right upper quadrant pain, fever, or jaundice which may indicate gallbladder disease, a reported adverse effect with tirzepatide [11] [12] Symptoms interfering with daily activities or causing significant distress despite conservative management Immediate emergency care is warranted for: Severe, unrelenting abdominal pain with vomiting Signs of acute pancreatitis (severe epigastric pain radiating to the back, fever, rapid pulse) Symptoms of severe dehydration or electrolyte imbalance (confusion, irregular heartbeat, muscle weakness) Suspected hypoglycemia with altered consciousness The FDA prescribing information specifically warns about the risk of acute kidney injury secondary to dehydration from gastrointestinal adverse effects

Dead nerves disrupt signals to and from the brain, interfering with physical and mental performance
doi: 10.1016/0022-3956(86)90009-9 20 ReynoldsE